Article Text

other Versions

PDF
Letter
Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis
  1. Camille Cohen1,
  2. Arsene Mekinian1,
  3. Nathalie Saidenberg-Kermanac'h2,
  4. Jerôme Stirnemann1,
  5. Pierre Fenaux3,
  6. Romain Gherardi4,
  7. Olivier Fain1
  1. 1Service de médecine interne, Université Paris 13, AP-HP, Hôpital Jean Verdier, 93140, Bondy, France
  2. 2Service de rhumatologie, Université Paris 13, AP-HP, Hôpital Avicenne, 93000, Bobigny, France
  3. 3Service d’hématologie, Université Paris 13, AP-HP, Hôpital Avicenne, 93000, Bobigny, France
  4. 4Service de pathologie, Université Paris 12, AP-HP, Hopital Henri Mondor, 94000, Créteil, France
  1. Correspondence to Camille Cohen, Hôpital Jean Verdier, médecine interne, Avenue du 14 juillet, Bondy, France, 93140; camille.c.cohen{at}gmail.com

Statistics from Altmetric.com

Cryoglobulinemia vasculitis is a small-vessel systemic vasculitis.1 The most common type is mixed cryoglobulinemia (MC), which is associated with hepatitis C virus (HCV), although autoimmune disorders such as systemic lupus erythematosus, primary Sjögren's syndrome or rheumatoid arthritis have also been described with MC.

A 51-year-old man had a diagnosis of anti-cyclic citrullinated peptide antibodies (anti-CCP) positive non-erosive rheumatoid arthritis in 2006 without cryoglobulinemia, and the disease was well controlled using leflunomide. Since April 2010, asthenia, muscular pain, arthralgias and bilateral foot paresthesias occurred. There was a presence of purpura with bilateral hypoesthesia in the common fibular nerve territory (left first toe levator weakness at 2/5), but no joint swelling. C-reactive protein and fibrinogen were …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.